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Available online xxxxAlzheimer's disease (AD), the predominant form of dementia, is highly correlated with the abnormal
hyperphosphorylation and aggregation of tau. Immune responses are key drivers of AD and how they contribute
to tau pathology in human disease remains largely unknown. This review summarises current knowledge on the
association between inﬂammatory processes and taupathology.While, preclinical evidence suggests that inﬂam-
mation can indeed induce tau hyperphosphorylation at both pre- and post-tangles epitopes, a better understand-
ing of whether this develops into advanced pathological features such as neuroﬁbrillary tangles is needed.
Microglial cells, the immune phagocytes in the central nervous system, appear to play a key role in regulating
tau pathology, but the underlying mechanisms are not fully understood. Their activation can be detrimental
via the secretion of pro-inﬂammatory mediators, particularly interleukin-1β, but also potentially beneﬁcial
through phagocytosis of extracellular toxic tau oligomers. Nevertheless, anti-inﬂammatory treatments in animal
models were found protective, but whether or not they affect microglial phagocytosis of tau species is unknown.
However, onemajor challenge to our understanding of the role of inﬂammation in the progression of tau pathol-
ogy is the preclinicalmodels used to address this question. Theymostly rely on the use of septic doses of lipopoly-
saccharide that do not reﬂect the inﬂammatory conditions experienced AD patients, questioning whether the
impact of inﬂammation on tau pathology in these models is dose-dependent and relevant to the human disease.
The use ofmore translationalmodels of inﬂammation corroboratedwith veriﬁcation in clinical investigations are
necessary to progress our understanding of the interplay between inﬂammation and tau pathology.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Lipopolysaccharide1. Introduction
Alzheimer's disease (AD) is classiﬁed under a group of neurodegen-
erative diseases termed tauopathies owing to its association with tau
pathology. Tau is a microtubule-associated protein predominately
expressed in neurons, which stabilizes microtubules under physiologi-
cal conditions, and as such regulates axonal stability and cell morpholo-
gy (Avila et al., 2004). Under pathological conditions such as AD, tau is
abnormally hyperphosphorylated leading to a decrease in its afﬁnity
for microtubules, a process represented in Fig. 1. Soluble
hyperphosphorylated tau then aggregates into pathological soluble
and insoluble aggregates known as neuroﬁbrillary tangles (NFT), a hall-
mark of AD. In addition toNFT, amyloid-beta (Aβ) plaques are identiﬁed
in AD brains, however cognitive decline correlates to a greater extent
with tau pathology (Schöll et al., 2016).C. Pardon).
Inc. This is an open access article
state of delirium: Decipherin
016/j.exger.2016.12.006Inﬂammation is considered a key mechanistic driver in AD where
both Aβ plaques and NFT co-localize with microglia and astrocytes,
the resident immune cells of the brain (Serrano-Pozo et al., 2011). Ge-
nomewide association studies (GWAS) suggest a strong association be-
tween AD and genes involved in the regulation of immunological
function (Lambert et al., 2013), whereas epidemiological studies have
revealed a reduced risk of developing the disease following long-term
anti-inﬂammatory treatments (Vlad et al., 2008) and disease-exacer-
bating effects of infectious agents (Honjo et al., 2009). Corroborating
these observations, pro-inﬂammatory stimuli have been shown to in-
duce both amyloid and tau pathologies in animal models (Zilka et al.,
2012).
To date, several randomised trials of anti-inﬂammatory agents have
been conducted in AD. Despite the use ofmultiple types anti-inﬂamma-
tory treatments, whether non-steroidal anti-inﬂammatory drugs
(NSAID) or steroidal, all have failed to demonstrate clear clinical efﬁcacy
in AD patients (Jaturapatporn et al., 2012). Pathogenesis in AD develops
years prior to symptommanifestation, and therefore, anti-inﬂammato-
ry agents were suggested to be beneﬁcial when administeredunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
g the effect of inﬂammation on tau pathology in Alzheimer's disease,
Fig. 1. Progression of tau pathology: Under physiological conditions tau regulatesmicrotubule stabilisation. In tauopathies, tau hyperphosphorylation triggers a loss inmicrotubule afﬁnity.
Soluble tau aggregates into pathological soluble tau oligomers, ultimately forming pathological insoluble neuroﬁbrillary tangles (NFT). Tau oligomers are secreted into the extracellular
compartment contributing to the propagation of tau pathology into neighbouring neurons. Inﬂammatory stimuli, such as Aβ, stimulate microglial production of pro-inﬂammatory
mediators such as IL-1β leading to the up-regulation of kinases involved in tau phosphorylation and exacerbation of the pathology. However, inﬂammation can have beneﬁcial effects
on tau pathology by inducing microglial phagocytosis of extracellular tau species. Image adapted from National Institute of Ageing.
2 M. Barron et al. / Experimental Gerontology xxx (2016) xxx–xxxprodromal. Although the largest trials assessing NSAIDs on subjects at
risk of developing AD have failed to show beneﬁts on AD incidence
(Breitner et al., 2013) a recent updated systematic review still argues
in favor of their use for prevention of AD (Wang et al., 2015).
The mechanisms underlying the involvement of immune responses in
AD pathogenesis remain poorly understood because inﬂammation has
both beneﬁcial and detrimental effects which can be very context depen-
dent (Heneka et al. 2016). Aβ pathology is exacerbated through the induc-
tion of pro-inﬂammatory mediators secreted from active immune cells
such as microglia (Brugg et al., 1995) but conversely, activation of these
cells can stimulate clearance of Aβ plaques via induction of phagocytosis
(Fiala et al., 2007), demonstrating a dual role for inﬂammation on amyloid
pathology. Less is known about the speciﬁc role of inﬂammatory processes
on tau pathology, and to our knowledge, the effect of anti-inﬂammatory
treatments on tau pathogenesis in humans is unknown. In preclinical
models inﬂammation is generally seen as an exacerbating factor (Zilka et
al., 2012) but recent data suggest that it may be beneﬁcial as well
(Majerova et al., 2014). Here, we will review the preclinical ﬁndings to
shed light on the interplay between inﬂammation and tau pathology in AD.
2. Inﬂammation induces tau phosphorylation
Table 1 summarises the outcomes of studies assessing the effect of
pro-inﬂammatory stimuli on tau pathology.
2.1. Systemic immune stimuli induce neuroinﬂammation
The majority of our understanding for the role played by inﬂamma-
tion on tau pathology relies on the use of systemic immune challenges,Please cite this article as: Barron, M., et al., A state of delirium: Decipherin
Exp. Gerontol. (2016), http://dx.doi.org/10.1016/j.exger.2016.12.006and particularly of the toll-like receptor 4 (TLR-4) agonist; lipopolysac-
charide (LPS) which fails to cross the blood brain barrier (Banks and
Robinson, 2010), thereby mimicking systemic infections. LPS neverthe-
less induces central inﬂammatory responses through a variety of includ-
ing neural routes such as vagal afferents, humoral routes through
circumventricular organs, inﬁltration of peripheral monocytes and
through effects on brain endothelial cells (Miller and Raison, 2016;
Pardon, 2015), and as such can affect tau pathology.
2.2. Inﬂammation induces tau phosphorylation in tau models
The ﬁrst direct evidence for a role of inﬂammation in exacerbating
tau pathology stemmed from in vitro studies with primary microglial
cells stimulated with Aβ or LPS prior to being co-cultured with primary
neocortical neurons (Li et al., 2003). This landmark study showed that
secretion of the pro-inﬂammatory cytokine interleukin-1β (IL-1β) by
microglial stimulation causes an increase in tau phosphorylation
through activation of p38-mitogen-activated protein kinases (MAPK).
This has been conﬁrmed in vivo predominantly using the 3xTg model
which exhibits both tau and amyloid pathologies (Oddo et al., 2003).
A chronic treatment regimen with LPS (0.5 mg/kg twice a week for
6 weeks) triggered tau hyperphosphorylation at multiple phosphoryla-
tion sites associated with both pre- and post-tangle tau pathology in
3xTg mice, and at both early and advanced pathological stages
(Kitazawa et al., 2005; Sy et al., 2011). Again, microglial activation and
resulting secretion of IL-1βwere implicated, via activation of either cy-
clin dependent kinase-5 (CDK-5) (Kitazawa et al., 2005) or glycogen
synthase kinase-3β (GSK-3β) (Sy et al., 2011). The discrepancy in the
kinases involved is likely due to differences in age and pathologicalg the effect of inﬂammation on tau pathology in Alzheimer's disease,
Table 1
Studies reporting the effect of inﬂammation on tau pathology.
Model Challenge Time to cull Effect on tau Kinases
implicated
Reference
Primary neuronal and microglia
cultures
LPS (30 ng/ml) n/a Tau phosphorylation (epitope not
speciﬁed)
↑P38 MAPK Li et al. (2003)
Primary neuronal and microglia
cultures
IL-1β (30 ng/ml) n/a Tau phosphorylation (epitope not
speciﬁed)
– Li et al. (2003)
3xTg-AD (Amyloid + Tau) LPS (6 weeks, twice per week,
0.5 mg/kg, i.p.)
24 h ↑pT231/pS235, ↑CDK5, Kitazawa et al.
(2005)↑pS202/pT205, =GSK-3β,
=pS396/404 =JNK,
=p38 MAPK
3xTg-AD (Amyloid + Tau) LPS (6 weeks, twice per week,
0.5 mg/kg, i.p.)
48 h ↓Total tau, ↑GSK-3β Sy et al. (2011)
↑pS202/pT205, =CDK5
↑pS214,
↑pT212/pS214,
=pT212
↑pS396/404 containing insoluble tau
3xTg-AD (Amyloid + Tau) MHV (i.p.) 2 weeks/4 weeks ↑pS396/404 ↑GSK-3β,
Sy et al. (2011)↑CDK5
rTg4510 (Tau) LPS (10 μg, i.c.v) 1 weeks ↑pS199/pS202, – Lee et al. (2010)
↑pS396,
=Insoluble tau
hTau (Tau) LPS (1 mg/kg, i.p.) 24 h ↑pS202/pT205, – Bhaskar et al.
(2010)↑pT231
C57BL/6 (WT) LPS (10 mg/kg, i.p.) 24 h ↑pS202/pT205, – Bhaskar et al.
(2010)↑pT231,
↑pS396/404
C57BL/6 (WT) LPS (100 μg/kg, i.p.) 0–4 h Transient: ↑pS396/404, ↑GSK-3β, Roe et al. (2011)
↑CDK5,
=ERK2,
=JNK↑pS202/pT205
3xTg-AD (Amyloid + Tau) R-ﬂurbiprofen (10 mg/kg, daily, 2 m,
chow)
– =pS202 – Carreras et al.
(2013)=ps202/pT205
↓ps396/404
3xTg-AD (Amyloid + Tau) Ibuprofen (daily, 5 months, chow) – ↓ps202/pT205 – McKee et al.
(2008)
hTau (Tau) Minocycline (10 mg/kg daily, 14d, i.p.) 2 h ↓ps202, – Noble et al. (2009)
↓pS396/404
↓ Insoluble tau
Bold indicates tau phosphorylation epitopes associated with post-tangle pathology (Augustinack et al., 2002).
3M. Barron et al. / Experimental Gerontology xxx (2016) xxx–xxxstages between the two studies. Infection with an altered murine hepa-
titis virus (MHV) strain likewise triggered an increase in tau phosphor-
ylation demonstrating the ability of both bacterial and viral immune
stressors to induce tau phosphorylation (Sy et al., 2011). Chronic over-
expression of another pro-inﬂammatory cytokine, tumor necrosis fac-
tor-α (TNFα), also caused an increase in the pre-tangle-associated
pT231 epitope (Janelsins et al., 2008). But in contrast, when the pro-in-
ﬂammatory cytokine interferon-γ (IFNγ), which is predominately asso-
ciated with viral infections, was overexpressed, tau dephosphorylation
occurred at pre-tangle associated phosphorylation sites (Mastrangelo
et al., 2009). Altogether, this suggests that whether or not inﬂammation
triggers exacerbation of tau pathology is, at least in part, dependent on
the nature of immunological stressor and the pro-inﬂammatory cyto-
kine involved. However, the fact that chronic treatment with the
NSAIDS: ibuprofen or r-ﬂurbiprofen were found to induce tau dephos-
phorylation at post-tangle associated phosphorylation epitopes
(Carreras et al., 2013; McKee et al., 2008), despite their poor brain pen-
etration (Parepally et al., 2006), suggests that basal peripheral inﬂam-
mation contributes to the development tau pathology.
While the 3xTg model is useful for studying interactions between
amyloid and tau pathologies, tau speciﬁc models are valuable to deci-
pher whether inﬂammation directly affects tau pathology. One such
model is the rTG4510 mouse which expresses a repressible form of
human tau containing the P301Lmutation that has been linkedwith fa-
milial frontotemporal dementia (SantaCruz et al., 2005). An intra-hip-
pocampal injection of 10 μg of LPS in these mice resulted in an
increase in tau phosphorylation persisting for at least seven days post
injection (Lee et al., 2010), conﬁrming that neuroinﬂammation can di-
rectly modulate tau phosphorylation independently of amyloidPlease cite this article as: Barron, M., et al., A state of delirium: Decipherin
Exp. Gerontol. (2016), http://dx.doi.org/10.1016/j.exger.2016.12.006pathology. Models in which a mutated form of tau is expressed exhibit
a more severe pathology than those based on non-mutated tau, al-
though they are of lower relevance to AD. The hTau model expresses
all 6 non-mutated tau isoforms as in AD, leading to pathological tau ag-
gregation (Andorfer et al., 2003). Both pre- and post-tangle phosphory-
lation sites were shown to be increased following a 1mg/kg dose of LPS
in the hTau model, demonstrating that the disease-exacerbating effect
of inﬂammation is not caused by tau mutations per se (Bhaskar et al.,
2010). To address the mechanisms involved, the authors used hTau
mice deﬁcient for the fractalkine receptors which are exclusively
expressed on microglial cells in the central nervous system and
known to stimulate anti-inﬂammatory and pro-phagocytic responses
(Medina and Ravichandran, 2016). This intervention exacerbated the
impact of LPS on tau phosphorylation (Bhaskar et al., 2010), again
supporting a role for microglia function in pathological tau phosphory-
lation, but also suggesting that activation of the protective immunosup-
pressive and phagocytic phenotype of microglia could be beneﬁcial to
tau pathology.
2.3. LPS induces tau phosphorylation in wild-type (WT) mice
While transgenic models provide relevance to pathogenesis of
human tau, the use of wild-type (WT) mice has proved useful to exam-
ine LPS effects on non-pathogenic tau. Interestingly, a low 100 μg/kg
dose of LPS was found to induce CDK5-dependent tau phosphorylation
at post-tangle associated epitopes as early as 20min post-injection, and
which subsidedwithin 4 h (Roe et al., 2011) indicating that low levels of
inﬂammation are sufﬁcient to transiently trigger tau phosphorylation.
Conversely, Bhaskar et al., 2010 demonstrated that a septic dose of LPSg the effect of inﬂammation on tau pathology in Alzheimer's disease,
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24 h following administration in WT mice. The failure to observe tau
hyperphosphorylation could be attributed to the use of a later time-
point than Roe et al. (2011). However, when the mice were deﬁcient
of the fractalkine receptor, the same 10 mg/kg dose, an increase in
microglial activation and tau phosphorylation was seen 24 h later at
both pre- and post-tangle sites, and IL-1 receptor signalling was again
found to be the underlyingmechanism (Bhaskar et al., 2010). Taken to-
gether, these ﬁndings demonstrate that pro-inﬂammatory stimuli in-
duce tau hyperphosphorylation at epitopes associated with both pre-
and post-tangle pathology in both WT and transgenic models of AD.3. What constitutes an alteration in tau pathogenesis?
3.1. Are changes in tau phosphorylation sufﬁcient to draw conclusions on
tau pathology?
Tau phosphorylation represents amechanistic trigger for a patholog-
ical cascade which ultimately leads to the development of NFT. Both
pre- and post-tangle associated phosphorylation epitopes were found
to be induced following immune stimulation as summarized in Fig. 2,
therefore the question arises as to the relative importance of speciﬁc
phosphorylation epitopes. Indeed the association between tau phos-
phorylation and development of pathology is poorly understood, with
increases in tau phosphorylation not always developing into tau aggre-
gation. For instance, Lee et al. (2010) showed in the rTG510 model that
while tau phosphorylation was increased following acute central LPS
administration, tau aggregation remained unaffected. This indicates
that assessing tau phosphorylation is not necessarily representative of
an impact on tau pathology. In contrast, Sy et al. (2011) reported an in-
crease in tau aggregation following a chronic LPS treatment regimen in
the 3xTGmodel. Interestingly the same phosphorylation epitopes were
affected in the two studies (Lee et al., 2010; Sy et al., 2011) possibly
demonstrating a role of acute vs. chronic effects, although a role for am-
yloid in the latter study cannot be ruled out. In support of this hypothe-
sis, a chronic reduction in basal inﬂammation induced through the
tetracycline antibiotic: minocycline reduced levels of both phosphory-
lated and aggregated tau in the hTau model (Noble et al., 2009). Recent
advancements have suggested tau oligomers as the tau species with the
greatest pathogenic potential, with their accumulation at the synapses,
rather than NFT, being thought to cause synaptic dysfunction
(Guerrero-Muñoz et al., 2015). Tau oligomers have the unique ability
to translocate across the synapse, propagating tau pathology into
healthy neighbouring neurons in a process known as tau seeding
(Guerrero-Muñoz et al., 2015). Assessing the effect of inﬂammation on
extracellular tau specieswill enable greater insight into our understand-
ing of the effects of inﬂammation on tau pathology.Fig. 2. Tau phosphorylation siteswhich have been shown to be affected by inﬂammatory stimuli
indicates increase and= indicates no change. ↑= indicates an increase or unaltered dependin
from (Augustinack et al., 2002).
Please cite this article as: Barron, M., et al., A state of delirium: Decipherin
Exp. Gerontol. (2016), http://dx.doi.org/10.1016/j.exger.2016.12.0063.2. Do inﬂammatory processes have a protective role in the development of
tau pathology?
While the literature to date points towards a detrimental role of in-
ﬂammation in exacerbating tau pathology, recent evidence suggests a
novel beneﬁcial role. As observed with amyloid pathology, this is attrib-
uted to microglial phagocytosis of tau species. Indeed, Majerova et al.
found that both primary and immortalised microglial cells stimulated
with LPS can phagocyte synthetic extracellular tau oligomers
(Majerova et al., 2014). While this demonstrates that microglia have
the propensity to phagocytose tau oligomers, caution is required as
the concentration of the oligomers used wasmuch greater than physio-
logical in vivo concentrations (Majerova et al., 2014). C57BL/6 mice
injected with both soluble and aggregated human tau likewise
show microglial internalization of both species of tau (Bolos et al.,
2015). Since the soluble tau injected included both monomeric and
oligomeric tau, this provides indirect evidence that microglia have the
potential to phagocytose toxic tau oligomers. Inﬂammation could
therefore be providing a beneﬁcial effect through inhibiting the spread
of tau pathology by microglial phagocytosis of extracellular tau seeds
as described in Fig. 1.
4. Is the inﬂammatory response modelled relevant to AD?
Thedata discussed above points towards dose-dependency in the ef-
fects of inﬂammation on tau pathology, questioning the relevance of the
stimuli used to model AD pathogenesis. LPS doses higher than 1 mg/kg
are considered to simulate sepsis rather than infection (Thomas et al.,
2014), a condition less frequently observed in AD patients. Only one
study used a dose below this threshold, 100 μg/kg, which is thought to
reﬂect mild systemic infection (Murray et al., 2012) and only resulted
in transient increases in tau phosphorylation (Roe et al., 2011). While
chronic LPS treatment regimens, as used by Kitazawa et al. (2005),
might be more relevant to AD pathogenesis, tolerance occurs with re-
peated LPS injections (Pardon, 2015), and this has to be taken into ac-
count when trying to identify which inﬂammatory processes
contribute to the tau pathology. Furthermore, LPS models only bacterial
infections, which is not representative of the range of inﬂammatory
conditions experienced by AD patients.
4.1. Concluding remarks
Inﬂammation has been suggested to play a role in the development
of tau pathology, but the underlyingmechanisms remain poorly under-
stood.While IL-1β signalling inmicroglia appears to be detrimental, the
data discussed here questions the pertinence of using tau phosphoryla-
tion as a readout for tau pathology. Pro-inﬂammatory stimuli robustly: Bold sites indicate post-tangle compared to pre-tangle associated phosphorylation sites. ↑
g on the study. Picture adapted from (Barré and Eliezer, 2013) and phosphorylation states
g the effect of inﬂammation on tau pathology in Alzheimer's disease,
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progresses into the pathological process of tau aggregation is largely un-
known. Novel evidence also suggests a beneﬁcial role for inﬂammation
on tau pathology through induction of microglial phagocytosis of tau
oligomers, with the potential to inhibit the spread of tau pathology.
Thus, suppressing the immune system could prove paradoxical at path-
ological stages of AD by potentiating tau pathological seeding into
healthy neurons (Heneka et al., 2016). Finally, the doses at which LPS
were found to induce tau phosphorylation inmice aremore representa-
tive of sepsis in humans, indicating that a substantial inﬂammatory re-
sponse is needed to induce tau pathology in pre-clinical models.
Through modelling mild and chronic infection akin to that seen in AD,
we will be able to better understand the role played by inﬂammation
in pathogenesis and treatment of AD.
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